OTC medicine monograph: Loperamide hydrochloride
This OTC medicine monograph outlines the requirements for Australian market authorisation of oral medicines containing loperamide hydrochloride as a single active ingredient when applied for as an OTC New Medicine N2 application. Proposed medicines must comply with all aspects of the monograph relevant to their strength and dosage form to qualify for evaluation as an N2 application.
This monograph should be read in conjunction with the document Requirements for OTC new medicine N2 applications.
This monograph only applies to medicines containing loperamide hydrochloride (CAS no. 34552-83-5) and excludes preparations containing any other salts and derivatives of loperamide.
Acceptable dosage forms and strengths are shown in the table below.
|Active substance||Dosage strengths||Dosage forms (excludes modified release dosage forms)|
|Loperamide hydrochloride||2 mg||Hard capsules, tablets (uncoated, film coated)|
Symptomatic treatment of acute non-specific diarrhoea.
The following label indications/claims are acceptable:
- 'Diarrhoea relief'
- 'Effective relief of/from diarrhoea'
- 'Symptomatic relief of/from diarrhoea'
- Reference to 'loose motions'
- 'Relief within 1-3 hours'
Note: Reference to 'fast', 'rapid' or similar is not acceptable.
Adults and children 12 years and over: 2 tablets/capsules initially, followed by 1 tablet after each loose motion, to a maximum of 8 tablets/capsules per day.
Do not give to children under 12 years of age.*
*This is a RASML statement.
Labelling must comply with all relevant Australian regulatory requirements, as detailed in the document Requirements for OTC new medicine N2 applications, including all required warning statements.
The following advisory statements are required#:
- If the condition persists after two days of treatment, seek medical advice as soon as possible.
- If you are pregnant or breastfeeding, check with your doctor or pharmacist before using this medicine.##
- Drink plenty of fluids as fluid and electrolyte depletion may occur with diarrhoea. If dehydration is suspected seek medical attention.
- Do not take if you have a medical condition where constipation should be avoided.
- See your doctor or pharmacist before taking [this medicine/insert name of medicine] if you have a fever, severe stomach pain, bloody diarrhoea or ongoing condition affecting the bowel.
# The above advisory statements are included in RASML Schedule 2.
## This statement will be revised pending a final outcome on a RASML consultation to change the pregnancy and breastfeeding warning statement for loperamide.
In addition to the quality requirements outlined in the document Requirements for OTC new medicine N2 applications, the following specific requirements apply to loperamide hydrochloride monograph medicines:
If the total weight of the tablet or capsule exceeds 100 mg (i.e. active ingredient is less than 2% w/w of the dosage form), the manufacturing process must have been validated on a minimum of two production batches in accordance with the requirements of GMP, prior to submission of the application . An assurance that this has been done must be provided with the application.
In addition to other requirements specified in the document Requirements for OTC new medicines N2 applications, the finished product specifications must comply, at a minimum, with the relevant set of requirements below.
The requirements below include all relevant BP general monograph/USP General Chapter requirements and TGO78 requirements. Further reference to these is not required.
References to pharmacopoeial monographs below refer to the current monograph at time of application.
The tests and limits in the USP monograph Loperamide Hydrochloride Tablets with the addition of:
- tablet appearance
- tighter limits for loperamide hydrochloride content of 92.5-107.5% (in accordance with TGO 78)
- Loperamide N-oxide (NMT 2% wrt loperamide hydrochloride)2
- microbiological quality, in compliance with TGO 77
The tests and limits in the BP monograph Loperamide Capsules3 with the addition of:
- capsule appearance
- microbiological quality, in compliance with TGO 77
- In accordance with manufacturing process validation requirements for 'microdose' products, as detailed in section 5.2.1 of Appendix 2 of the ARGOM
- Use assay method specified for Loperamide Hydrochloride Capsules BP, or an alternative equivalent or superior method. The method must be appropriately validated as described in Requirements for OTC new medicine N2 applications.
- Including dissolution test, with a limit of NLT 70% in 45 min, in accordance with Appendix XII B. Monographs of the British Pharmacopoeia.
- If a measuring device is to be supplied with the product, calibrations must be exclusively in metric units and must allow all the doses shown on the labels to be measured accurately. Details of the calibrations on the measuring device must be provided with the submission (a sample may also be requested). Further considerations and requirements regarding measuring devices are detailed in ARGOM Appendix 2: Guidelines on quality aspects of OTC applications, 8. Finished product container.
© Commonwealth of Australia 2014
This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted under the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <firstname.lastname@example.org>.
|Version||Description of change||Author||Effective date|
|V1.0||Original publication||OTC Medicines Evaluation/Office of Medicines Authorisation||16/12/2014|